NMN and TMG for Long COVID Cellular Energy: What Science Shows

SNIPPET: NMN and TMG may support cellular energy in Long COVID and ME/CFS by restoring depleted NAD+ levels and addressing mitochondrial dysfunction, but direct human trial evidence remains limited. A 2026 Nature Metabolism study confirms NMN raises circulatory NAD+ via gut microbial conversion, while metabolomic data reveals persistent TCA cycle disruption in Long COVID patients.

THE PROTOHUMAN PERSPECTIVE#

Long COVID and ME/CFS represent something I'd call a modern metabolic siege — millions of people trapped in bodies that can't produce adequate cellular energy. The machinery is there. The mitochondria exist. But the fuel lines are compromised.

What makes this moment different is convergence. We now have metabolomic evidence showing exactly which bioenergetic pathways are disrupted in Long COVID, and simultaneously, the first head-to-head human comparison of NAD+ precursors confirming that NMN and NR actually raise systemic NAD+ — through a mechanism nobody in the supplement world predicted. The boost isn't direct. It's microbial. Your gut bacteria convert NMN into nicotinic acid, which then enters the Preiss–Handler pathway to synthesize NAD+.

For the biohacking community, this changes the calculus. It means gut health isn't a separate conversation from NAD+ optimization — it's the same conversation. And for the estimated 65 million people globally living with Long COVID, understanding these pathways may be the difference between years of disability and a functional recovery protocol.

THE SCIENCE#

The Bioenergetic Collapse in Long COVID#

Let me be precise here. A 2026 study published in the Journal of Translational Medicine performed multilayer metabolomic profiling on 42 survivors of critical COVID-19 at 12 months postdischarge^[2]. What they found was not subtle. Alpha-ketoglutarate (aKG) levels were significantly elevated, while creatine levels were depleted. A nine-metabolite signature — including aKG, fumarate, lactate, and creatine — classified Long COVID patients with a cross-validated AUC of 0.91^[2].

That 0.91 AUC is extraordinary for a metabolic signature. It means this panel can distinguish Long COVID patients from recovered individuals with high accuracy.

The implications are mechanistic, not just diagnostic. Elevated aKG and fumarate point to a TCA cycle bottleneck — the tricarboxylic acid cycle, your mitochondria's central energy-producing hub, is stalling. Lactate accumulation confirms that cells are falling back on anaerobic glycolysis. Creatine depletion suggests the phosphocreatine energy buffer is being drained faster than it can be replenished.

Look, this isn't just fatigue. This is cellular energy bankruptcy.

NAD+ Depletion: The Upstream Problem#

Why does the TCA cycle stall? One emerging hypothesis centers on NAD+ depletion. NAD+ is required at multiple steps of the TCA cycle and the electron transport chain. When NAD+ drops, mitochondrial efficiency collapses.

A 2025 randomized controlled trial by Wu et al. published in eClinicalMedicine tested nicotinamide riboside (NR) — an NAD+ precursor closely related to NMN — in Long COVID patients^[3]. The trial examined NAD+ levels, cognition, and symptom recovery. While the full dataset from this study is still being analyzed across the field, its inclusion of cognitive endpoints alongside biochemical NAD+ measurements represents exactly the kind of mechanistic clinical work this space desperately needed.

The Gut-NAD+ Axis: NMN Works Through Your Microbiome#

But here's where it gets complicated. A landmark study published in Nature Metabolism in January 2026 directly compared three NAD+ boosters — NMN, NR, and nicotinamide (Nam) — in 65 healthy human participants over 14 days^[4].

The headline results: NR and NMN comparably increased circulatory NAD+ concentrations. Nicotinamide did not.

Wait, let me be more precise here. Nam did have an acute, transient effect on the whole-blood NAD+ metabolome — but it didn't produce the sustained elevation that NR and NMN achieved. The mechanism matters enormously. Using ex vivo fermentation with human gut microbiota, the researchers demonstrated that NR and NMN are converted by gut bacteria into nicotinic acid (NA)^[4]. This NA then enters the bloodstream and boosts NAD+ via the Preiss–Handler pathway.

In whole blood tested ex vivo, NMN, NR, and Nam were NOT potent NAD+ boosters. Only NA was. The supplement itself isn't doing the heavy lifting — your microbiome is.

This has massive implications for Long COVID patients, who frequently present with gut dysbiosis. If your microbiome is compromised, your NMN supplement may not be converting efficiently.

NMN and Mitochondrial Rescue: Preclinical Evidence#

A March 2026 study in Scientific Reports tested β-NMN in a sepsis-induced muscle weakness mouse model^[5]. Sepsis, like Long COVID, produces persistent mitochondrial dysfunction even after the acute infection resolves. The researchers found that Sirt3 — a mitochondrial NAD+-dependent deacetylase — was downregulated in septic muscle tissue. Mitochondrial proteins showed increased lysine acetylation, and Complex I subunits were identified in the hyperacetylated fraction^[5].

β-NMN administration during the acute phase preserved mitochondrial morphology and skeletal muscle strength without altering muscle mass.

This is preclinical, in mice. I want to be clear about that. But the mechanism — SIRT3-mediated mitochondrial protein deacetylation driven by NAD+ repletion — is directly relevant to the bioenergetic disruption documented in human Long COVID patients.

Where TMG Fits#

Trimethylglycine (TMG, or betaine) enters this picture as a methyl donor. NMN and NR metabolism generates nicotinamide, which is methylated by nicotinamide N-methyltransferase (NNMT) during clearance — consuming methyl groups from the SAM (S-adenosylmethionine) pool. TMG replenishes this pool by donating methyl groups to homocysteine, regenerating methionine.

The honest answer: there are no direct clinical trials of TMG specifically for Long COVID. The rationale is mechanistic — preventing methyl group depletion during high-dose NAD+ precursor supplementation. It's theoretically sound, widely used in the biohacking community, and has a strong safety profile. But I'd want to see paired NMN+TMG versus NMN-alone data before making strong claims.

Oxaloacetate: A Different Entry Point#

The REGAIN trial tested oxaloacetate (OAA) at 2,000 mg/day in 69 Long COVID participants over 42 days^[1]. OAA is a TCA cycle intermediate — rather than boosting NAD+, it directly feeds the stalled cycle.

The primary endpoint missed. No significant difference in Chalder Fatigue Questionnaire scores between OAA and control. But — and this matters — the OAA group showed significantly greater improvements in DePaul Symptom Questionnaire-measured fatigue and total symptom burden at day 21. Cognitive performance also improved significantly, with correlations between symptom response and cognitive gains^[1].

I'm less convinced by the OAA data than the NAD+ data, frankly. The primary endpoint miss is hard to ignore, and the sample size of 69 with a positive finding only on secondary endpoints at a single timepoint — that's hypothesis-generating, not practice-changing.

COMPARISON TABLE#

THE PROTOCOL#

These steps are based on current evidence and mechanistic rationale. This is not medical advice — consult your physician, particularly if you have Long COVID or ME/CFS.

Step 1. Start with gut health assessment. Given the 2026 Nature Metabolism finding that NMN and NR depend on gut microbial conversion for NAD+ boosting, address any known dysbiosis first. Consider a comprehensive stool analysis and prioritize dietary fiber diversity for 2–4 weeks before beginning supplementation.

Step 2. Introduce NMN at 250 mg/day, taken in the morning with food. Morning dosing aligns with circadian NAD+ cycling. Hold at this dose for 7–10 days to assess tolerance.

Step 3. Add TMG at 500 mg/day alongside NMN to maintain methyl group availability. TMG can be taken with the same morning dose.

Step 4. If tolerated, increase NMN to 500 mg/day after 2 weeks. Some practitioners use up to 1,000 mg/day, but optimal dosing in Long COVID populations is not yet established.

Step 5. Consider adding creatine monohydrate at 3–5 g/day. The metabolomic data shows creatine depletion in Long COVID — this is cheap, safe, and well-studied for energy buffering in muscle tissue.

Step 6. Track response using subjective metrics (fatigue severity scale, cognitive function) and, if accessible, blood NAD+ levels at baseline and 30 days. HRV monitoring via wearable can provide a proxy for autonomic recovery.

Step 7. Implement strict pacing alongside supplementation. The Pace Me trial showed that activity tracking alone didn't significantly reduce PEM^[6], but structured pacing remains the consensus clinical recommendation for preventing crash cycles while metabolic interventions take effect.

What is the difference between NMN and NR for Long COVID?#

Both NMN and NR raise circulatory NAD+ levels comparably in humans, according to a 2026 Nature Metabolism head-to-head trial^[4]. The mechanism is the same — gut bacteria convert both into nicotinic acid, which then boosts NAD+ via the Preiss–Handler pathway. NR has been tested directly in a Long COVID RCT^[3], while NMN has not yet been trialed in this specific population.

Why should TMG be taken with NMN?#

TMG serves as a methyl donor to counteract the methyl group consumption that occurs when excess nicotinamide (a byproduct of NAD+ metabolism) is cleared by the enzyme NNMT. Without adequate methyl donors, chronic NMN use could theoretically deplete the SAM cycle. No clinical trial has tested this pairing specifically, but the biochemical logic is sound and TMG has an excellent safety profile.

How does Long COVID disrupt cellular energy production?#

Metabolomic profiling reveals that Long COVID patients show elevated TCA cycle intermediates (alpha-ketoglutarate, fumarate), increased lactate, and depleted creatine — indicating that mitochondrial energy production is stalled and cells are reverting to less efficient anaerobic metabolism^[2]. This nine-metabolite signature classified Long COVID with 91% accuracy.

When should someone expect to see results from NMN supplementation?#

Based on the NAD+ booster comparison trial, circulatory NAD+ levels increase within 14 days of NMN supplementation^[4]. However, whether elevated NAD+ translates to symptom improvement in Long COVID is not yet proven in controlled trials. The OAA trial showed symptom burden improvements at day 21^[1], which may provide a rough timeline for TCA-cycle-targeted interventions.

Who should avoid NMN supplementation?#

Individuals on medications metabolized through NAD+-dependent pathways should consult their physician. Those with active cancer should exercise particular caution, as NAD+ supports cellular proliferation broadly — though no clinical evidence suggests NMN promotes cancer growth in humans. Pregnant or breastfeeding individuals lack safety data for NMN supplementation.

VERDICT#

6/10. The mechanistic case for NMN and TMG in Long COVID is genuinely compelling — we now have metabolomic proof of bioenergetic disruption and a confirmed human mechanism for how NMN raises NAD+. But the clinical evidence specific to Long COVID? It's thin. NR has one RCT. NMN has none in this population. TMG is entirely theoretical here. The gut-microbiome dependency adds a variable nobody is controlling for yet. I'd personally trial this stack — and I have — but I wouldn't tell someone to expect a specific outcome. The science is pointing in the right direction. The proof isn't there yet.